Magic bullet, part III?
In this issue of Blood, Oliveri and colleagues and Magro and colleagues report pilot trials using imatinib for steroid refractory sclerotic cGVHD,showing response rates of 79%and 50%.
Vogelsang
Georgia B
GB
Johns Hopkins University, Baltimore, MD, USA.